At first sight, the chart for Universal Ibogaine Inc., which is traded as IBOGF on the OTC markets and IBO.V…

The tax system has finally acknowledged what most drivers already knew—that a £42,000 family electric car isn’t a luxury—after some…

The way Atai stock moved this week has an almost theatrical quality. Most traders outside the small psychedelic biotech circle…

In the corners of finance Twitter, there is a specific type of stock that has been written off, relisted as…

Watching a stock like QXO makes you feel a little off. Two years ago, the ticker hardly existed at all.…

There’s something peculiar about strolling through downtown Indianapolis and discovering that one of the world’s most valuable pharmaceutical companies is…

When HIMS began to tick up in aftermarket trading late on a Friday in early March, it was the first…

Somewhere outside of Montevideo, the lights remain on and the wind farms continue to run during the dry months when…

You’ll notice an odd contradiction if you walk into nearly any mid-sized office right now. The screens have more content.…

The launch took place in Brooklyn, of all places, and Jimmy Fallon warmed up a crowd that, by all accounts,…

AbbVie’s identity was largely dependent on a single molecule for many years. The immunology blockbuster Humira, which was once the…

Over the past year, a certain silence has descended upon the marketing floors of a number of major consumer goods…